bluebird bio Reports Fiscal First Quarter 2014 Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended March 31, 2014.

"The first quarter of 2014 has been very productive for bluebird bio," said Nick Leschly, chief bluebird. "We treated the first beta-thalassemia major subject in our U.S. based Northstar Study with LentiGlobin, opened an IND for our sickle cell disease study and we are now presenting preliminary beta-thalassemia major data at the upcoming European Hematology Association Congress.

Help employers find you! Check out all the jobs and post your resume.

Back to news